Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

ClinicalTrials.gov ID: NCT00334152

Public ClinicalTrials.gov record NCT00334152. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis

Study identification

NCT ID
NCT00334152
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
515 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2006
Primary completion
Jun 30, 2006
Completion
Jun 30, 2006
Last update posted
Mar 22, 2017

2006

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
25
Facility City State ZIP Site status
GSK Investigational Site Fairhope Alabama 36532
GSK Investigational Site Mobile Alabama 36608
GSK Investigational Site Montgomery Alabama 36106
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Arcadia California 91007
GSK Investigational Site Glendale California 91206
GSK Investigational Site Laguna Hills California 92653
GSK Investigational Site Pasadena California 91105
GSK Investigational Site Boca Raton Florida 33067
GSK Investigational Site Melbourne Florida 32901
GSK Investigational Site Miami Florida 33143
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Chicago Illinois 60637
GSK Investigational Site Kansas City Kansas 66160
GSK Investigational Site Baltimore Maryland 21229-5299
GSK Investigational Site Royal Oak Michigan 48073
GSK Investigational Site Mineola New York 11501
GSK Investigational Site New Hyde Park New York 11040
GSK Investigational Site New York New York 10038
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Cincinnati Ohio 45208
GSK Investigational Site Oklahoma City Oklahoma 73104
GSK Investigational Site Charlottesville Virginia 22908
GSK Investigational Site Winchester Virginia 22601
GSK Investigational Site Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00334152, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 22, 2017 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00334152 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →